Literature DB >> 14209774

CLINICAL TRIALS OF HYDROXYUREA IN PATIENTS WITH CANCER AND LEUKEMIA.

W N FISHBEIN, P P CARBONE, E J FREIREICH, D MISRA, E FREI.   

Abstract

Entities:  

Keywords:  BLOOD PLATELETS; HEMOGLOBIN; LEUKEMIA; LEUKEMIA, MYELOCYTIC; LEUKOCYTE COUNT; NEOPLASM THERAPY; PHARMACOLOGY; UREA

Mesh：

Substances：

Year:  1964        PMID： 14209774     DOI： 10.1002/cpt196455574

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  6 in total

Review 1.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

Review 2.  An overview of bone marrow transplantation for chronic myeloid leukemia.

Authors:  M J Barnett; A C Eaves; G L Phillips
Journal:  CMAJ       Date:  1990-08-01       Impact factor: 8.262

3.  Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.

Authors:  W P Vaughan; C Holm; K Cordel
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Hydroxyurea, leucopheresis, and splenectomy in chronic myeloid leukaemia at the problastic phase.

Authors:  L Schwarzenberg; G Mathé; P Pouillart; R Weiner; J Locour; J Genin; M Schneider; F De Vassal; M Hayat; J L Amiel; J R Schlumberger; C Jasmin; C Rosenfeld
Journal:  Br Med J       Date:  1973-03-24

5.  Studies with hydroxyurea. VII. Hydroxyurea and the synthesis of functional proteins.

Authors:  H S Rosenkranz; E B Winshell; A Mednis; H S Carr; C J Ellner
Journal:  J Bacteriol       Date:  1967-10       Impact factor: 3.490

Review 6.  Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.

Authors:  Giovanna Cannas; Solène Poutrel; Xavier Thomas
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-02-15       Impact factor: 2.576
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.